GoodRx Holdings, Inc. Class A Common Stock

Day range

$3.48 – $3.60

Open

$3.55

Prev close

$3.54

Volume

473.76K

Market cap

$1.21B

Shares out

104.71M

P/E

74.32

P/S

1.54

P/B

1.86

P/FCF

7.26

ROE

2.5%

ROA

0.7%

Debt/Equity

0.75

Div yield

0.00%

As of Oct 23, 2026

• Cfo departureAug 5, 2026

  On July 31, 2026, GoodRx Holdings, Inc. (the "Company") determined that Christopher McGinnis will transition from his role of Chief Financial Officer & Treasurer, effective as of 11:59 p.m. Eastern Time on August 5, 2026. Mr. McGinnis's departure is not a result of any disagreement with the Company on any matter relating to the Company's operating performance, financial reporting, accounting, internal controls, operations, policies, or practices.

• Quarterly earningsAug 5, 2026

  On August 5, 2026, GoodRx Holdings, Inc. (the "Company") announced the Company's financial results for the three and six months ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this report.

• Annual meeting resultsJun 18, 2026

  On June 16, 2026, GoodRx Holdings, Inc. held its Annual Meeting of Stockholders... the Company's stockholders (i) elected Wendy Barnes, Ronald E. Bruehlman and Gregory Mondre as Class III directors; (ii) ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and (iii) approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.

• Executive compensation changeApr 24, 2026

  In connection with his appointment, the Board approved an annual base salary increase to $310,000, with a target annual bonus of 40% of his base salary. In addition, Mr. Chan will be granted (i) a restricted stock unit award ("RSU Award") having an aggregate value of $131,250 and (ii) a performance-based restricted stock unit award ("PSU Award") having an aggregate value of $43,750 under the Company's 2020 Incentive Award Plan.

• Director departureApr 3, 2026

  On March 31, 2026, Ian T. Clark notified GoodRx Holdings, Inc. (the "Company") of his decision to resign as a member of the Company's Board of Directors (the "Board"), including his service on the Board's Nominating & Governance Committee, effective as of March 31, 2026. Mr. Clark has indicated to the Company that his decision to resign is not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies or practices.

Days to cover

5.4

Short interest

4.16M

Avg volume

773.44K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue
  negativeThe Motley Fool· May 10, 2026
• GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market
  positiveBenzinga· Apr 15, 2026
• Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings.
  positiveThe Motley Fool· Feb 5, 2026
• Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
  positiveBenzinga· Jan 5, 2026
• Novo Nordisk Leans Into Affordability Amid Rising Competition
  positiveBenzinga· Nov 17, 2025